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INTRODUCTION
Hematopoiesis allows the formation of blood cells from a hematopoietic stem cell (HSC) through a stepwise process, and occurs at different sites through ontogeny in mice and humans [1] .
During mouse embryogenesis, definitive HSCs capable of reconstituting adult irradiated recipients are generated at embryonic day (E) 10.5-E11.5 from the ventral wall of the dorsal aorta-gonad-mesonephros (AGM) [2] , from the umbilical vein [3] and from the placenta [4] . Due to the constant migration of HSCs through blood circulation during development, an incomplete picture remains regarding which locations constitute de novo HSC production sites and which are pre-HSC-to-HSC maturation sites. At approximately E12.5, HSCs colonize the fetal liver (FL) to further migrate to the bone marrow (BM) where they reside for the lifespan of the organism [1] .
In the murine and human settings, the transplantation assay is the in vivo gold standard test to study HSC function. HSC transplantation is widely employed in experimental and clinical
hematology, and refinement of HSC transplantation assays have resulted in improved HSC engraftment/read-out. For instance, murine HSC transplantation is now optimized to be performed at the single cell level, and has been crucial in revealing the functional heterogeneity of murine and human HSC compartments. In the mouse, HSC transplantation assays are mainly performed by intravenous (IV) administration due to the intrinsic circulatory properties of hematopoietic cells. Successful engraftment then requires blood circulation and migration of HSCs into the BM, which offers a supportive niche. Alternatively, direct injection of cells within the BM has been successfully employed to engraft human HSCs [5] [6] [7] [8] , leukemia cells [9, 10] and mesenchymal sarcoma cells [11, 12] in immunodeficient mice. Intra-BM transplantation (IBMT) has shed light on the homing and repopulation properties of human HSCs, and has been shown to result in higher levels of multilineage long-term reconstitution than IV injection. IBMT also This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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allows detection of HSC potential from non-hematopoietic tissues, such as liver, muscle, and human pluripotent stem cells (hPSCs). Interestingly, IBMT has also been employed with whole murine BM cells [13, 14] ; however, in one study IBMT did not result in an enhanced engraftment compared with the IV technique [15] .
Recently, the group of Daley tested the impact of HSC ontogeny (embryonic vs adult) and the recipient's age (newborn or adult) on the engraftment potential upon transplantation [16] . They showed that embryonic HSCs from E9.5-10.5 preferentially engrafted neonatal mice. Despite the wide use of IBMT in the HSC xenotransplantation setting, no studies so far have assessed the engraftment ability of murine hematopoietic cells of embryonic origin by these different administration routes. We hypothesized that IBMT could represent a superior strategy to detect/read-out hematopoietic reconstitution of embryonic cells given their scarcity at early stages of development. Indeed, limiting dilution assays have reported that an AGM at E11.5 contains approximately one definitive HSC [17] . In this study, we have compared the ability of IV and IBMT administration of E11.5 AGM cells to reconstitute the hematopoiesis in a syngeneic transplantation setting. Our data shows that IBMT confers superior multi-lineage engraftment of murine AGM cells over IV transplantation, thus offering an improved read-out to study early developmental hematopoiesis function.
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Transplantation
Prior to transplantation, IBMT recipients were analgesized subcutaneously (2 mg/kg meloxicam and 0.1 mg/kg buprenorfina) and anesthesized by 4% isofluorane inhalation. For IBMT injections, the femur-tibia joint was perforated with a 25G needle and subsequently cells were injected into the retrieved orifice with a 27G needle in a volume of 25 µL [5, 18] . IV injections were performed in the lateral tail vein in a volume of 200 µL [5] . One fresh AGM embryo equivalent (ee) CD45. 
Donor chimerism analysis in PB and tissues
PB was collected from the facial vein directly into EDTA tubes. Red blood cell (RBC) lysis was performed using QuickLysis (Cytognos, Salamanca, Spain). Cells were then stained in PBS+5%
FCS with fluorochrome-conjugated antibodies. CD45.1-APC and CD45.2-APC-Cy7 were used for allotype discrimination in transplanted mice. In multi-lineage analysis, cells were stained with
Mac-1-V450, B220-PE-Cy7 and CD4/CD8-PE for myeloid, B-cell and T-cell analysis, respectively.
Cells were analyzed using a FACS Canto II cytometer (BD Bioscience) and FlowJo software (Tree Star).
For BM analysis, femurs and tibiae were harvested and pooled from IV recipients. For IBMT recipients, injected tibiae (IT) were harvested separately from the remaining femur and from bones of the contralateral limb. A BM cell suspension was obtained by crushing the bones and Table S1 .
Statistical Analysis
Data are expressed as mean±s.e.m of independent experiments. Statistical comparisons were performed using either paired or unpaired Student's t test as appropriate. Statistical significance was defined as P-value<0.05. Kaplan-Meier plots representing donor engraftment-assisted survival were calculated using SPSS software [19] .
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Regardless of the administration route, a donor multi-lineage (myeloid, B-cell and T-cell) engraftment was consistently observed (Fig. 1C) . The increased engraftment observed in PB of IBMT-transplanted mice was accompanied by enhanced donor reconstitution in other hematopoietic tissues at 18 weeks post-transplantation (BM: 54±7% vs 28±10%; spleen, 79±10% vs 49±17%; thymus: 90±9% vs 47±20%, IBMT vs IV, respectively. P<0.05 for pooled tissues, Fig. 1D ).
The IBMT administration route did not skew the reconstitution pattern of the donor-engrafted cells since a similar percentage of myeloid (Gr-1 + ), B (B220 + ) and T (CD4 + /CD8 + ) cells was found within the CD45.2 + graft in BM, spleen and thymus ( Fig. 2A,B) . However, the percentage of donor cells within the Lineage -Sca-1 + c-kit + (LSK) compartment, which comprises the pool of immature stem and progenitor cells in the mouse hematopoietic system [20] , was 50%-60% higher upon IBMT transplantation (Fig. 2C, left panel) . Similarly, the percentages of CD45.2 + within the Sca-1 + c-kit -and c-kit + Sca-1 -compartments were higher in IBMT over IV-transplanted 
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IBMT confers higher hematopoietic reconstitution in secondary recipients and in limiting dilution experiments.
To prove bona fide E11.5 AGM-derived HSC self-renewal and multi-lineage differentiation, primary IV and IBMT grafts (6 million unfractionated BM cells from 18-week primary recipients)
were serially IV-transplanted into secondary recipients [21] (Fig. 3A) and hematopoietic reconstitution was assessed in the PB of secondary recipients at different time points after transplantation. Primary IBMT grafts resulted in consistently higher PB chimerism levels in secondary recipients as compared with primary IV grafts (65%-90% vs 38%-52%, P<0.05, (Fig. 3D) . We then assessed whether IBMT administration facilitates the engraftment of lower doses of AGM cells (Fig. 3E) . IBMT-transplanted 1 ee and 0.5 ee conferred 40% and 23%, respectively, multilineage hematopoietic engraftment-assisted 20-week survival. In contrast, equivalent AGM doses IV-transplanted conferred 25% and 7% engraftment, respectively, after 20 weeks (Fig. 3F) . These results confirm that IBMT administration facilitates the read-out of hematopoietic reconstitution of embryonic tissues with very-low HSC content.
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DISCUSSION
Early in embryogenesis, hematopoietic stem and progenitor cells (HSPCs) such as those derived from yolk sac, AGM or ESCs, are very poorly represented due to either their scarcity or low developmental potential [17, 22] . Definitive HSCs emerge from the AGM, and AGM-derived HSCs are the first cells reconstituting hematopoiesis in an irradiated adult animal [23] . Assessing the hematopoietic potential and plasticity of early AGM-derived cells relies on robust and sensitive in vivo long-term functional assays, and transplantation into irradiated mice is considered the in vivo gold standard test of HSC functionality. Although HSPC transplantation assays are commonly performed by IV administration, direct injection of cells into the BM is an alternative modality that has been used successfully to engraft human HSCs [5] [6] [7] . IBMT-based HSC delivery is, however, less common in the mouse syngeneic setting.
Here we compared the ability of IBMT and IV administration of AGM-derived cells to reconstitute the hematopoietic system of myeloablated recipients. In contrast to the IV route, IBMT administration resulted in significantly higher levels of AGM HSC long-term multilineage engraftment in all analyzed hematopoietic tissues of primary and secondary recipients.
Importantly, the multilineage contribution pattern was not skewed in any hematopoietic organ by the IBMT administration route, suggesting that IBMT does not impair in vivo HSPC differentiation and migratory properties. However, IBMT conferred higher LSK long-term engraftment, in line with the superior IBMT reconstitution. Importantly, multilineage reconstitution was barely observed after 20 weeks when 0.5 ee were IV-transplanted, but was detected in 23% of the IBMT-transplanted mice receiving 0.5 ee. Our study indicates that IBMT represents a superior administration route to detect HSC activity for many applications, including when a limited number 
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of HSCs are available from developmentally early sources such as the AGM, and when studying BM niche-HSC interactions [24] . We envision that the potential advantage of IBMT over IV might be: i) it bypasses the requirement for homing to the BM niche; ii) it facilitates survival within the niche;
and iii) it prevents transplanted cells from being taken up by organs in vivo as occurs with intravenouslyinjected cells.
Recently, Daley and coworkers' demonstrated that recipient age influences the engraftment of embryonic HSCs [16] by showing that IV injection of AGM cells into neonatal recipients yielded a more robust engraftment than in adult recipients. Another study demonstrated that intrahepatic transplantation of human CB-CD34 + cells into newborn immunodeficient mice provided enhanced hematopoietic engraftment without the requirement of accessory cells [25] . Our data suggest that IBMT transplantation of AGM cells in adult recipients may be used as an alternative modality to overcome the logistics of matching recipient's age with the nature of donor cells. The group of Ikehara have also compared IBMT and IV transplantation in mouse models. They showed that IBMT constitutes a powerful strategy in several scenarios, including treatment for autoimmune diseases [26] . Similarly, Li et al. analyzed the kinetics of hematopoietic reconstitution very early after IBMT or IV transplantation and found more donor-derived cells in IBMT-transplanted animals [14] . They also analyzed the long-term maintenance of donor-derived hematopoiesis after IBMT or IV using serial transplantation, and found that the frequency of donor-derived HSPCs was higher in IBMT-than in IV-transplanted tertiary recipients [13] . Additionally, Baba et al., used serial transplantation assays to demonstrate how IBMT accelerates donor cell engraftment and proliferation, and also facilitates reconstitution of dendritic cells [27] . In contrast to our results, de
Haan's group showed that IBMT transplantation in a murine syngeneic setting does not provide enhanced engraftment in comparison with IV administration [15] . A likely explanation for this Whether IBMT is superior to IV in terms of engraftment for other embryonic tissues, such as yolk sac, placenta, fetal liver or ESC-derived cells, remains unknown. Likewise, the engraftment potential of IBMT-transplanted ex vivo expanded AGM cells needs to be investigated in future studies. In the clinical setting, several trials have assessed the benefit of allogeneic transplantation using IV or IBMT administration [28] . One study observed reduced risk and severity of acute graft-versus-host disease in the IBMT cohort. Moreover, a 20-year follow-up trial concluded that intraosseus infusion of BM cells was a safe and efficient procedure [29] . Thus, we envision that IBMT will become the administration route of choice in experimental and clinical hematology. 
ACKNOWLEDGMENTS AND FINANCIAL SUPPORT:
CONFLICT OF INTEREST:
The authors have no conflict of interest to disclose. All authors have read and approved the manuscript in its present form.
Page 12 of 22
Stem Cells and Development
